Medifast to Report Q1 Earnings: What Investors Should Expect
Werte in diesem Artikel
Medifast, Inc. MED is likely to register a decrease in both top and bottom lines when it reports first-quarter 2025 earnings on April 28, after market close. The Zacks Consensus Estimate for first-quarter revenues is pegged at $119.9 million, which indicates a 31.4% decline from the year-ago quarter’s reported figure.Although the consensus mark for first-quarter bottom line has narrowed by 13 cents in the past 30 days to a loss of 7 cents, the projection indicates deterioration from 66 cents reported in the year-ago quarter. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)MED delivered a trailing four-quarter earnings surprise of 152.6%, on average. In the last reported quarter, the company surpassed the Zacks Consensus Estimate by a margin of 137%.MEDIFAST INC Price, Consensus and EPS Surprise MEDIFAST INC price-consensus-eps-surprise-chart | MEDIFAST INC QuoteKey Factors to Note Before MED’s Upcoming Earnings ReleaseMedifast continues to face a difficult macroeconomic environment, marked by mounting competitive pressures within the health and wellness industry, the disruptive impact of GLP-1 weight loss medications and a broader decline in consumer discretionary spending. These challenges are likely to have prevailed and clouded the company’s performance in the to-be-reported quarter.On its fourth-quarter earnings call, management projected revenues between $100 million and $120 million for the first quarter of 2025, reflecting the sustained difficulties in attracting new customers and maintaining coach engagement. This downside can be attributed to evolving dynamics of the weight loss market, with the rapid uptake of GLP-1 therapies continuing to alter consumer preferences and behavior.Medifast’s bottom line is also likely to have been negatively impacted in the first quarter. The company projected the bottom line to be between break-even and a loss of 50 cents. This guidance underscores the financial strain resulting from declining sales volumes, elevated customer acquisition costs and continued investment in strategic initiatives.Despite the ongoing challenges, Medifast has been actively pursuing a range of strategic initiatives to reignite its growth momentum. The company has focused on broadening its product portfolio, diversifying customer acquisition strategies and enhancing the overall consumer experience. MED has been realizing benefits from its "Fuel for the Future" program, an enterprise-wide cost optimization initiative designed to improve operational efficiency. These strategic actions are likely to have provided some cushion against the broader pressures faced during the quarter under review.What the Zacks Model Predicts for MEDOur proven model does not conclusively predict an earnings beat for Medifast this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Medifast currently has a Zacks Rank #3 and an Earnings ESP of 0.00%.Stocks With the Favorable CombinationHere are some companies which, according to our model, have the right combination of elements to beat on earnings this time around.Sprouts Farmers Market, Inc. SFM currently has an Earnings ESP of +0.44% and a Zacks Rank of 1. You can see the complete list of today’s Zacks #1 Rank stocks here. SFM's top line is anticipated to increase year over year when it reports first-quarter 2025 results. The Zacks Consensus Estimate for its quarterly revenues is pegged at $2.19 billion, which implies 16.3% growth from the year-ago quarter’s reported figure. The company is expected to register an increase in the bottom line. The consensus estimate for Sprouts Farmers’ first-quarter earnings is pegged at $1.53 per share, indicating 36.6% growth from the year-ago quarter. SFM delivered a trailing four-quarter earnings surprise of 15.1%, on average.BJ's Wholesale Club Holdings, Inc. BJ presently has an Earnings ESP of +2.09% and a Zacks Rank of 2. BJ's top line is anticipated to advance year over year when it reports first-quarter fiscal 2025 results. The Zacks Consensus Estimate for its quarterly revenues is pegged at $5.18 billion, which indicates a 5.3% increase from the year-ago quarter’s reported figure. The company is expected to register growth in the bottom line. The consensus estimate for BJ's Wholesale Club’s fiscal first-quarter earnings is pegged at 91 cents per share, implying an increase of 7.1% from the year-ago quarter. BJ delivered a trailing four-quarter earnings surprise of 12%, on average.Freshpet FRPT currently has an Earnings ESP of +2.56% and a Zacks Rank of 3. The company is likely to register top-line growth when it reports first-quarter 2025 numbers. The Zacks Consensus Estimate for Freshpet’s quarterly revenues is pegged at $262.3 million, which indicates nearly 17.2% growth from the prior-year quarter.The company is expected to register a decrease in the bottom line. The consensus estimate for Freshpet’s first-quarter earnings is pegged at 13 cents per share, indicating a 38.1% decrease from the year-ago quarter. FRPT delivered a trailing four-quarter earnings surprise of 78.8%, on average.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BJ's Wholesale Club Holdings, Inc. (BJ): Free Stock Analysis Report Freshpet, Inc. (FRPT): Free Stock Analysis Report Sprouts Farmers Market, Inc. (SFM): Free Stock Analysis Report MEDIFAST INC (MED): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: Medifast und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf Medifast
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Medifast
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Medifast Inc.
Analysen zu Medifast Inc.
Datum | Rating | Analyst | |
---|---|---|---|
15.09.2017 | Medifast Buy | D.A. Davidson & Co. | |
07.11.2014 | Medifast In-line | Imperial Capital | |
25.09.2006 | Update Medifast Inc.: Outperform | Ryan, Beck & Co | |
16.03.2005 | Update Medifast Inc.: Hold | Seidler |
Datum | Rating | Analyst | |
---|---|---|---|
15.09.2017 | Medifast Buy | D.A. Davidson & Co. | |
25.09.2006 | Update Medifast Inc.: Outperform | Ryan, Beck & Co |
Datum | Rating | Analyst | |
---|---|---|---|
07.11.2014 | Medifast In-line | Imperial Capital | |
16.03.2005 | Update Medifast Inc.: Hold | Seidler |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Medifast Inc. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen